Eosinophilic annular erythema: A striking clinical presentation with potential systemic implications

Gray, DO Taylor; Lee, BS Joelle; Segars, DO Kelly; Knopp, Eleanor A.; Miller, DO Richard

doi:10.1016/j.jdcr.2021.07.034

Cited by 2 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although EAE is typically considered a benign condition with a good prognosis, the relapsing and remitting cycles and associated patient discomfort warrant a therapeutic attempt. Moreover, there is some postulation of systemic implications of EAE, with cases of concomitant autoimmune disease, cancer, and vasculitis being reported in the literature [1,6]. Given there is no standard treatment for this condition, several options have been reported including hydroxychloroquine, systemic corticosteroids, topical steroids, narrow-band UVB, dapsone, and dupilumab [1,7].…”

Section: Discussionmentioning

confidence: 99%

Eosinophilic Annular Erythema Responding to Doxycycline

Young,

Chung,

Fett

2023

Cureus

View full text Add to dashboard Cite

Eosinophilic annular erythema (EAE) is a rare skin disease characterized by relapsing and remitting pruritic, annular erythematous plaques and tissue eosinophilia. A 39-year-old male presented with a mildly pruritic, relapsing, and remitting urticarial rash. A biopsy revealed superficial and deep perivascular dermatitis with numerous eosinophils and some neutrophils, with an absence of flame figures. Based on clinical and histopathologic findings, the patient was given a diagnosis of eosinophilic annular erythema. Treatment was initiated with doxycycline 100 mg twice daily. The patient reported substantial improvement at three months and sustained clearance at one year, remaining on doxycycline well tolerated throughout. To our knowledge, no cases of EAE improving with doxycycline have been reported in the literature and, thus, our findings highlight a potential new therapy to consider in a patient with EAE.

show abstract

Section: Discussionmentioning

confidence: 99%

Eosinophilic Annular Erythema Responding to Doxycycline

Young,

Chung,

Fett

2023

Cureus

View full text Add to dashboard Cite

show abstract

“…En la literatura se menciona su asociación con enfermedad tiroidea autoinmune, hepatitis autoinmune, borreliosis crónica, carcinoma de celulares renales, cáncer de próstata, gastritis crónica por Helicobacter pylori, hepatitis C, enfermedad renal crónica, e incluso, diabetes mellitus; no obstante, hasta la fecha, no se han corroborado estas asociaciones etiológicas en el desarrollo del eritema anular eosinofílico. 2,4…”

Section: Epidemiología Y Fisiopatologíaunclassified

Eritema anular eosinofílico

Cardona-Hernández,

Ramos-Garibay,

de Anda-Ortíz

2023

Revista Del Centro Dermatológico Pascua

View full text Add to dashboard Cite

El eritema anular eosinofílico es una dermatosis eosinofílica aguda, benigna, poco común y de evolución recurrente. En la actualidad existe controversia en si se trata de una entidad independiente, un subtipo del síndrome de Wells o un síndrome de Wells subdiagnosticado per se. Fue descrita por primera vez en 1981 por Peterson y Jarrat en un paciente pediátrico, y fue hasta el año 2000 cuando Kahofer y colaboradores describieron el primer caso en un paciente adulto.

show abstract

Eosinophilic annular erythema: A striking clinical presentation with potential systemic implications

Cited by 2 publications

References 12 publications

Eosinophilic Annular Erythema Responding to Doxycycline

Eosinophilic Annular Erythema Responding to Doxycycline

Eritema anular eosinofílico

Contact Info

Product

Resources

About